BR0318503A - substituted quinolines as protein tyrosine kinase enzyme inhibitors - Google Patents

substituted quinolines as protein tyrosine kinase enzyme inhibitors

Info

Publication number
BR0318503A
BR0318503A BRPI0318503-6A BR0318503A BR0318503A BR 0318503 A BR0318503 A BR 0318503A BR 0318503 A BR0318503 A BR 0318503A BR 0318503 A BR0318503 A BR 0318503A
Authority
BR
Brazil
Prior art keywords
tyrosine kinase
protein tyrosine
enzyme inhibitors
kinase enzyme
substituted quinolines
Prior art date
Application number
BRPI0318503-6A
Other languages
Portuguese (pt)
Inventor
Allan Wissner
Sridhar Krishna Rabindran
Hwei-Ru Tsou
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34435322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0318503(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0318503A publication Critical patent/BR0318503A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"QUINOLINAS SUBSTITUìDAS COMO INIBIDORES DE ENZIMA PROTEìNA TIROSINA CINASE". A presente invenção refere-se aos compostos de fórmula (I), contendo uma estrutura em que R~ 1~, R~ 2~, R~ 3~ são descritos na especificação. Os compostos agem como agentes anticâncer por inibição de HER-2 e EGFR."QUINOLINS REPLACED AS PROTEIN TYROSINE KINASE ENZYME INHIBITORS". The present invention relates to compounds of formula (I), containing a structure wherein R1-, R2-, R3- are described in the specification. The compounds act as anticancer agents by inhibiting HER-2 and EGFR.

BRPI0318503-6A 2003-09-15 2003-10-15 substituted quinolines as protein tyrosine kinase enzyme inhibitors BR0318503A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66227303A 2003-09-15 2003-09-15
PCT/US2003/032612 WO2005034955A1 (en) 2003-09-15 2003-10-15 Substituted quinolines as protein tyrosine kinase enzyme inhibitors

Publications (1)

Publication Number Publication Date
BR0318503A true BR0318503A (en) 2006-09-12

Family

ID=34435322

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0318503-6A BR0318503A (en) 2003-09-15 2003-10-15 substituted quinolines as protein tyrosine kinase enzyme inhibitors

Country Status (7)

Country Link
EP (1) EP1670473A1 (en)
AU (1) AU2003304497B2 (en)
BR (1) BR0318503A (en)
CA (1) CA2537978C (en)
MX (1) MXPA06002846A (en)
UA (1) UA85394C2 (en)
WO (1) WO2005034955A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102886045A (en) 2005-02-03 2013-01-23 综合医院公司 Method for treating gefitinib resistant cancer
EP1883631A1 (en) * 2005-05-25 2008-02-06 Wyeth Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof
AR057854A1 (en) 2005-11-04 2007-12-19 Wyeth Corp ANTINEOPLASTIC COMBINATIONS WITH MTOR INHIBITOR, HERCEPTINE AND / OR HKI-272 (E) -N- {4- [3-CHLORINE-4- (2-PIRIDINILMETOXI) ANILINO] -3-CIANO-7-ETOXI-6-QUINOLINIL} -4- (DIMETHYLAMINE) -2-BUTENAMIDE
JP2009533405A (en) * 2006-04-14 2009-09-17 アストラゼネカ アクチボラグ 4-anilinoquinoline-3-carboxamide as CSF-1R kinase inhibitor
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2915532B1 (en) 2008-06-17 2016-10-19 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
JP5681108B2 (en) 2008-08-04 2015-03-04 ワイス・エルエルシー 4-Anilino-3-cyanoquinoline and capecitabine antineoplastic combination
CN101723854A (en) 2008-10-24 2010-06-09 上海特化医药科技有限公司 Preparation method of 6-substituted amino-3-cyano quinoline compound and midbody thereof
RU2011139363A (en) 2009-04-06 2013-05-20 ВАЙЕТ ЭлЭлСи BREAST CANCER TREATMENT SCHEME USING NERATINIB
GB0922302D0 (en) * 2009-12-22 2010-02-03 Imp Innovations Ltd Compounds
CN102146084B (en) * 2010-02-04 2014-05-07 江苏恒瑞医药股份有限公司 3-cyan-6-aminoquinoline derivatives, preparation method thereof and application thereof in medicines
WO2012127441A1 (en) 2011-03-23 2012-09-27 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
CN102718679B (en) * 2011-03-30 2016-06-08 北京万全阳光医药科技有限公司 That preparation method replacing Buddhist nun's key intermediate of a kind of promise
CN102731395B (en) * 2011-04-15 2015-02-04 中国科学院上海药物研究所 Intermediate compound of antitumor drug neratinib and its preparation method and use
CN104080774B (en) 2012-01-17 2017-02-22 安斯泰来制药株式会社 Pyrazine carboxamide compound
CN104926669A (en) * 2014-03-18 2015-09-23 江苏豪森医药集团连云港宏创医药有限公司 Preparation method of trans-4-dimethylaminocrotonic acid hydrochloride
WO2019042409A1 (en) * 2017-09-01 2019-03-07 上海医药集团股份有限公司 Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application
CN110357854A (en) * 2018-03-26 2019-10-22 江苏创诺制药有限公司 A kind of preparation method of linatinib
CN111848581B (en) * 2020-08-19 2021-08-10 昆明学院 Preparation method of 3-cyano-4-anilino-6-aminoquinoline derivative
CN111943933B (en) * 2020-09-02 2021-05-28 重庆医科大学 Preparation method of neratinib impurity D
CN111995618B (en) * 2020-09-02 2021-06-11 重庆医科大学 Preparation method of neratinib impurity G
CN114920695B (en) * 2022-06-29 2023-06-20 深圳大学总医院 Quinazoline derivative, preparation method thereof, pharmaceutical composition and application

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
UA77469C2 (en) * 2001-11-27 2006-12-15 White Holdings Corp 3-cyanoquinolines as egf-r and her2 kinase inhibitors

Also Published As

Publication number Publication date
CA2537978A1 (en) 2005-04-21
CA2537978C (en) 2011-08-02
EP1670473A1 (en) 2006-06-21
AU2003304497A1 (en) 2005-04-27
WO2005034955A1 (en) 2005-04-21
UA85394C2 (en) 2009-01-26
MXPA06002846A (en) 2006-06-14
AU2003304497B2 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
BR0318503A (en) substituted quinolines as protein tyrosine kinase enzyme inhibitors
PE20050081A1 (en) NEW IMIDAZOPYRAZINES AS INHIBITORS OF CYCLINE-DEPENDENT KINASES
BRPI0412347A (en) 2-Aminophenyl-4-phenylpyridines as kinase inhibitors
BRPI0510777A (en) substituted indazoles, compositions containing them, production process and use
BRPI0412894A (en) thienopyridine and furopyridine kinase inhibitors
BR0309556A (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
BR0308339A (en) Indazoles Replaced with Anticancer Activity
BRPI0409164A (en) substituted pyrazoles
BRPI0413934A (en) organic compounds
CO5601019A2 (en) [6,7-BIS (2-METOXI-ETOXI) -QUINAZOLIN-4-IL] - (3-ETINYL-PHENYL) AMINA CLOHYDRATE POLYMORPH
EA200601007A1 (en) 7-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLYMERASE INHIBITORS (ADP-RIBOSE) INHIBITORS
TNSN08024A1 (en) 7-substituted aza-indazoles, compositions containing same, production method and use thereof
UY27234A1 (en) NOVELTY INHIBITORS OF TYROSINE KINASE
BRPI0417708A (en) organophosphoric derivatives of indazoles and their use as protein kinase inhibitors
BRPI0514841A (en) hedgehog signaling pyridyl inhibitors, their preparation process and composition comprising said inhibitors
BRPI0517435A (en) triazoles useful as protein kinase inhibitors
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
BRPI0506718A (en) compounds, process for preparing same, and pharmaceutical or cosmetic composition
TW200519096A (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
MXPA05013076A (en) Isoindolin-1-one compounds as kinase inhibitors.
ATE507218T1 (en) BENZODIAZEPINE DERIVATIVES AS ROCK KINASE INHIBITORS
BRPI0416030A (en) hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
BRPI0407913A (en) ccr-3 receptor antagonists
BR0309386A (en) Triaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinases inhibitors
BR0308419A (en) Azetidine derivatives as ccr-3 receptor antagonists

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 31/4706, C07D 215/54, C07D 401/12, C07D 417/12, C07D 407/12, C07D 413/12, C07D 405/12, C07D 409/12, A61K 31/4709, A61K 31/506, A61P 35/00

Ipc: A61K 31/4706 (2011.01), C07D 215/54 (2011.01), C07

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/10/2018, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24D Patent annual fee: restoration after fee payment
B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.004187/2021-24 ORIGEM: 31O VF DO RIO DE JANEIRO PROCESSO NO: 5031286-04.2021.4.02.5101 NULIDADE DE ATO ADMINISTRATIVO AUTOR: LIBBS FARMACEUTICA LTDA. REU(S): WYETH (US) E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.011680/2021-09 ORIGEM: 21A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1080400-66.2021.4.01.3400 ACAO PELO PROCEDIMENTO COMUM AUTOR: WYETH LLC REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL